TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17640422

Group type: EXPERIMENTAL
Intervention: Formula+LCP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Formula
Number of subjects: 30

Group type: COMPARATOR
Intervention: Formula (first 10 days of life)
Number of subjects: 30
Study: 15920053

Group type: EXPERIMENTAL
Intervention: Pancreas transplant alone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nontransplanted group
Number of subjects: 32
Study: 12747812

Group type: EXPERIMENTAL
Intervention: NPPV with standard mask connected to a BiPAP ventilatory assist device
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 41
Study: 10366795

Group type: EXPERIMENTAL
Intervention: More than 10x10(6) CD34+ cells/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fewer than 10x10(3) CD34+ cells/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CD34+/CD61+ megakaryocytic cell number
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CD34+/CD38Eth subset
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with platelet engraftment after day 20
Number of subjects: 80
Study: 8895640

Group type: EXPERIMENTAL
Intervention: Magnetic resonance venography (initial interpretation by staff radiologists)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Magnetic resonance venography (retrospective review by dedicated magnetic resonance angiographer)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard contrast venography
Number of subjects: 207
Study: 1825704

Group type: EXPERIMENTAL
Intervention: Cefotaxime-clindamycin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cefotaxime-metronidazole
Number of subjects: 38
Study: 6241622

Group type: EXPERIMENTAL
Intervention: Captopril (250 mg/day) for eight weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Captopril (125 mg/day) alone or combined with chlorthalidone (25 mg/day) for eight weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for two weeks
Number of subjects: 20
Study: 31749275

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg subcutaneous on the evening before surgery and 1.2 mg after induction of anaesthesia
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 278
Study: 30880176

Group type: EXPERIMENTAL
Intervention: 1 mg glepaglutide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg glepaglutide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.1 mg glepaglutide
Number of subjects: 18
Study: 27238825

Group type: EXPERIMENTAL
Intervention: Intraoral mask
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional cuffed face mask
Number of subjects: 27
Study: 26865601

Group type: EXPERIMENTAL
Intervention: ABA/MTX
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: ABA
Number of subjects: 351

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 351
Study: 24557425

Group type: EXPERIMENTAL
Intervention: Vasopressin + Hydrocortisone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Vasopressin + Placebo
Number of subjects: 61
Study: 22467883

Group type: EXPERIMENTAL
Intervention: Peer influence and conduct problems
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Family dysfunction
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Rejection sensitivity
Number of subjects: 417
Study: 19409339

Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (initially untreated)
Number of subjects: 174
Study: 17316115

Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy protein isolate (low-iso SPI; 1.64 +/- 0.19 mg iso/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-isoflavone soy protein isolate (high-iso SPI; 61.7 +/- 7.4 mg iso/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-isoflavone soy protein isolate (high-iso SPI)
Number of subjects: 35
Study: 15249363

Group type: EXPERIMENTAL
Intervention: ILM peeling with ICG staining
Number of subjects: 40

Group type: COMPARATOR
Intervention: ILM peeling without ICG staining
Number of subjects: 40
Study: 12471323

Group type: EXPERIMENTAL
Intervention: Aquatic exercise (N = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (N = 12)
Number of subjects: 24
Study: 9734752

Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oat bran
Number of subjects: 5
Study: 8034778

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/2% copolymer/0.243% sodium fluoride dentifrice
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control dentifrice (same formulation without triclosan)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan dentifrice
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both dentifrices
Number of subjects: 144
Study: 2566537

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30860588

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 79
Study: 28630086

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation therapy specifically adapted for Parkinson's‐related dementias (CST‐PD), involving 30 min sessions delivered at home by the study companion three times per week over 10 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 25224595

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (OC) combined with Caphosol(®)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral cryotherapy (OC) only
Number of subjects: 40
Study: 23834543

Group type: EXPERIMENTAL
Intervention: Short-term lifestyle activity modification (LAM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 21209397

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg qd
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg bid
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Oligofructose‐enriched inulin (ORAFTI®Synergy1) 6 gm bid
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (maltodextrin) 6 gm bid
Number of subjects: 85
Study: 19232138

Group type: EXPERIMENTAL
Intervention: Therapeutic Communication Program (TCom)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Waiting list control group (February group)
Number of subjects: 79
Study: 17065895

Group type: EXPERIMENTAL
Intervention: Perineural ropivacaine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Perineural normal saline
Number of subjects: 29
Study: 12921454

Group type: EXPERIMENTAL
Intervention: Guided imagery and relaxation therapy
Number of subjects: 10
Study: 10763948

Group type: EXPERIMENTAL
Intervention: Standardized multicomponent behavioral therapy plus standard medical treatment (SMBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard medical treatment alone (SMT)
Number of subjects: 24
Study: 8610798

Group type: EXPERIMENTAL
Intervention: Pelli‐Robson contrast sensitivity
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Snellen visual acuity
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Humphrey Field Analyzer mean deviation
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Farnsworth‐Munsell 100‐hue color vision
Number of subjects: 438
Study: 1376586

Group type: EXPERIMENTAL
Intervention: Energy-dense supplementary food with nutrition education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutrition education alone (Control)
Number of subjects: 0
Study: 6145368

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg/kg intravenously
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg intravenously
Number of subjects: 24
Study: 3730522

Group type: EXPERIMENTAL
Intervention: Fixed combination ('Tenoret 50')
Number of subjects: 12

Group type: COMPARATOR
Intervention: Free combination
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol tablet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chlorthalidone tablet
Number of subjects: 12
Study: 30073285

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (50% nitrous oxide and 50% oxygen inhaled for 40 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (50% nitrogen and 50% oxygen inhaled for 40 minutes)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 40
Study: 25770984

Group type: EXPERIMENTAL
Intervention: Cranial nerve injury (CNI) in patients undergoing CEA with general anesthesia (n=1040)
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Cranial nerve injury (CNI) in patients undergoing CEA with local anesthesia (n=111)
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Resolution of CNI at 1 month
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Resolution of CNI at 1 year
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: HRQOL evaluation for patients with CNI
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Difficulty eating/swallowing in patients with CNI
Number of subjects: 1151
Study: 23939841

Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment manoeuvre (two manual inflations to a maximum pressure of 60 cmH2 O)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard treatment (passive decompression via open operative ports)
Number of subjects: 76
Study: 19765239

Group type: EXPERIMENTAL
Intervention: Resistance training combined with vibration (VIB)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Resistance training alone (CON)
Number of subjects: 18
Study: 18250271

Group type: EXPERIMENTAL
Intervention: KAI-9803 (0.05 mg)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: KAI-9803 (0.5 mg)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: KAI-9803 (1.25 mg)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: KAI-9803 (5.0 mg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 16488388

Group type: EXPERIMENTAL
Intervention: Exposure + videotape feedback of performance (PER)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Exposure + videotape feedback of audience responses (AUD)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Exposure + no feedback (EXP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Credible placebo treatment (PLA)
Number of subjects: 77
Study: 12741878

Group type: EXPERIMENTAL
Intervention: Progressive resistance back extension exercise on a 45 degrees Roman chair once weekly for 12 weeks, one set of 8‐20 dynamic repetitions to volitional exhaustion using hand‐held metal plates for additional resistance
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 15
Study: 10834689

Group type: EXPERIMENTAL
Intervention: Gabexate mesylate (2 mg/kg/hr)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline (2 mL/hr; control group)
Number of subjects: 34
Study: 9003108

Group type: EXPERIMENTAL
Intervention: Educational brochure
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Lottery-type incentive
Number of subjects: 797

Group type: COMPARATOR
Intervention: Both educational brochure and incentive
Number of subjects: 797

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Educational brochure (for individuals who had not accepted immunization in the prior year)
Number of subjects: 797
Study: 1352563

Group type: EXPERIMENTAL
Intervention: Naftopidil 25 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Naftopidil 50 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6716470

Group type: EXPERIMENTAL
Intervention: Videotape about smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Videotape on a different health topic
Number of subjects: 0
Study: 30568303

Group type: EXPERIMENTAL
Intervention: APVAC1 vaccine derived from unmutated antigens
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: APVAC2 vaccine targeting neoepitopes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GAPVAC approach with poly-ICLC and GM-CSF as adjuvants
Number of subjects: 15
Study: 29857876

Group type: EXPERIMENTAL
Intervention: Horticultural therapy program (10 sessions, once weekly)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 27097076

Group type: EXPERIMENTAL
Intervention: A. dracunculus (1000 mg) before breakfast and dinner for 90 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24447459

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle counseling to parents of overweight children
Number of subjects: 637

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 637
Study: 23138652

Group type: EXPERIMENTAL
Intervention: Thoracoamniotic shunting using a double-basket catheter (1.47 mm diameter)
Number of subjects: 24
Study: 20467301

Group type: EXPERIMENTAL
Intervention: Home-based exercise prescription throughout the study
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Home-based exercise prescription after completing cancer treatment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119
Study: 17879957

Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 303

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: glucose concentrations at 120 min of the OGTT
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: glucose area below fasting values (GABF) at the end of the OGTT
Number of subjects: 303
Study: 15961983

Group type: EXPERIMENTAL
Intervention: Enfuvirtide 90 mg twice daily injected subcutaneously
Number of subjects: 628
Study: 12503709

Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIMV)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham NIMV
Number of subjects: 36
Study: 9622312

Group type: EXPERIMENTAL
Intervention: Periconceptional folic acid containing multivitamin supplementation
Number of subjects: 0
Study: 7857350

Group type: EXPERIMENTAL
Intervention: Pidotimod (800 mg orally, twice daily) plus antibiotic (amoxycillin plus clavulanic acid: 1 g twice daily)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (one sachet) plus antibiotic (amoxycillin plus clavulanic acid: 1 g twice daily)
Number of subjects: 137
Study: 2493433

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation
Number of subjects: 960

Group type: COMPARATOR
Intervention: Adjuvant tamoxifen
Number of subjects: 960
Study: 196167

Group type: EXPERIMENTAL
Intervention: Seda-Kneipp (a compound preparation of valerian and hops)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial treatment with 'strong' sleeping pills followed by 'weak' sleeping pills
Number of subjects: 0
Study: 31232810

Group type: EXPERIMENTAL
Intervention: Crossover anastomosis (CA) flaps
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DIEP-1 (1 perforator) flaps
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: MS-TRAM flaps
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DIEP-2 (2 perforators) flaps
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: MS-TRAM and DIEP-2 flaps
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DIEP-1 flaps
Number of subjects: 84
Study: 30145946

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 45 days
Number of subjects: 12019

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12019
Study: 26896073

Group type: EXPERIMENTAL
Intervention: True Waiguan acupuncture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham Waiguan acupuncture
Number of subjects: 24

Group type: COMPARATOR
Intervention: True needling of a nonacupoint
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham needling of a nonacupoint
Number of subjects: 24
Study: 24277115

Group type: EXPERIMENTAL
Intervention: Sonographic image-guided injection
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional anatomic landmark palpation‐guided injection
Number of subjects: 77
Study: 23143689

Group type: EXPERIMENTAL
Intervention: Telephone-based pharmacist intervention; education and counseling on medication adherence.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care (control group); no specific intervention mentioned.
Number of subjects: 95
Study: 18996225

Group type: EXPERIMENTAL
Intervention: Testosterone therapy for 6 months
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 252
Study: 17891537

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Levocetirizine 30 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 15302778

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) treatment
Number of subjects: 9974

Group type: EXPERIMENTAL
Intervention: Higher doses of UFH (>5000 U, or up to 90 U/kg)
Number of subjects: 9974

Group type: EXPERIMENTAL
Intervention: UFH weight‐indexed dose
Number of subjects: 9974
Study: 12670035

Group type: EXPERIMENTAL
Intervention: IVECG signal conducted from the guide wire (group G)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IVECG signal conducted from the transduction probe (group T)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group G (guide wire)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group T (transduction probe)
Number of subjects: 60
Study: 9066028

Group type: EXPERIMENTAL
Intervention: PRP conjugated to an outer membrane protein complex (PRP-OMP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PRP oligomers conjugated to CRM197 (HbOC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 8200218

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone 12 hours before surgical procedure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone 24 hours before surgical procedure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo 24 hours before interruption of pregnancy
Number of subjects: 60
Study: 3300475

Group type: EXPERIMENTAL
Intervention: Relaxation alone (progressive muscle relaxation and focused breathing)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Relaxation combined with mental imagery of the immune system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vigilance task (alertness or mild arousal control)
Number of subjects: 30
Study: 29049072

Group type: EXPERIMENTAL
Intervention: SGB with 5 mL of 0.5% mepivacaine
Number of subjects: 52

Group type: COMPARATOR
Intervention: SGB with 5 mL of normal saline
Number of subjects: 52
Study: 28550240

Group type: EXPERIMENTAL
Intervention: GSTP1 AA genotype
Number of subjects: 862
Study: 25594610

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate (0.1%) cream (BMVc)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.1%) ointment (TACo)
Number of subjects: 17
Study: 23984572

Group type: EXPERIMENTAL
Intervention: Pentax-AWS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study: 21911872

Group type: EXPERIMENTAL
Intervention: Individualized home exercise program (TG)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Phone calls twice per week for 12 weeks (CG)
Number of subjects: 35
Study: 19042328

Group type: COMPARATOR
Intervention: Psychoeducational Therapy (PET)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 88
Study: 16570038

Group type: EXPERIMENTAL
Intervention: S-1 combined with CPT-11 (irinotecan)
Number of subjects: 42
Study: 14642412

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 11113417

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonculprit arteries with abnormal flow
Number of subjects: 0
Study: 8953357

Group type: EXPERIMENTAL
Intervention: Operant behavioural management strategies (Condition 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mutual goal setting (Condition 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine nursing care (Condition 3)
Number of subjects: 0
Study: 8169547

Group type: EXPERIMENTAL
Intervention: Lumbar range of motion examination using the Orthoranger II digital inclinometer, conducted twice by each examiner (four times total per subject)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lumbar flexion measurement
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lumbar extension measurement
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lumbar lateral flexion measurement
Number of subjects: 28
Study: 3286342

Group type: EXPERIMENTAL
Intervention: Unrefined carbohydrate diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Refined carbohydrate diet
Number of subjects: 10
Study: 29975125

Group type: EXPERIMENTAL
Intervention: Local Vibration with Blood Flow Restriction (LV + BFR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Local Vibration (LV)
Number of subjects: 12
Study: 27958255

Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonobese group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consumption of egg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consumption of bovine liver
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consumption of mushroom
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consumption of red meat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMI correlation with vitB12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin resistance correlation with vitB12
Number of subjects: 0
Study: 24366167

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 466

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 466